RJA
SCPH

Raymond James & Associates’s scPharmaceuticals SCPH Stock Holding History

Raymond James & Associates’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$368K Sell
80,706
-5,353
-6% -$25.9K ﹤0.01% 3286
2024
Q2 		$374K Buy
86,059
+1,010
+1% +$4.44K ﹤0.01% 3245
2024
Q1 		$427K Sell
85,049
-2,000
-2% -$11.2K ﹤0.01% 3155
2023
Q4 		$546K Buy
87,049
+5,377
+7% +$30.8K ﹤0.01% 2909
2023
Q3 		$582K Buy
81,672
+4,420
+6% +$34.8K ﹤0.01% 2800
2023
Q2 		$787K Buy
77,252
+7,401
+11% +$77.2K ﹤0.01% 2631
2023
Q1 		$634K Buy
69,851
+18,093
+35% +$133K ﹤0.01% 2773
2022
Q4 		$371K Buy
+51,758
New +$316K ﹤0.01% 3085

Other funds holding SCPH

O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $488M AUM 327.32% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $23.1B AUM 21.31% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JGC
J. Goldman & Co New York $2.16B AUM 33.8% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return